Therefore, if silent progression by subclinical dying back degeneration occurs in patients with AQP4 + NMOSD, as we hypothesized, then biological disease-modifying drugs can prevent brain atrophy by decreasing the activity and lesion length in the spinal cord. This evidence concerns the gene AQP4 and Brain atrophy.